There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease–sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes–the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as “metabolic syndrome” where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer’s disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.
Buy a copy of this report @ http://www.reportsnreports.com/reports/75197-diabetes-metabolic-syndrome-and-cardiovascular-disease.html.
Table of Contents:
4. Pharmaceutical Industry and the Anti-Diabetes Market
4.1 The Worldwide Pharmaceutical Industry 56
4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure 56
4.1.2 Global Pharmaceutical Market 58
4.2 Total Diabetes Drug Market Size and Growth 62
4.2.1 Sales of Anti-Diabetic Drugs Continue to Rise 65
4.3 Diabetic Medications Overview 66
4.3.1 Recent Trends in Diabetic Drug Usage 67
4.3.2 Market Influence Factors 71
5. Non-Insulin Anti-Diabetes Products
5.1 Anti-Diabetic Drug Therapy Overview 73
5.1.1 Sulfonylureas 77
5.1.2 Meglitinides 78
5.1.3 Biguanides 79
5.1.4 Thiazolidinediones (TZDs) 80
5.1.5 ?-Glucosidase Inhibitors 82
5.1.6 Incretin Mimetics/Glucagon-like Peptide (GLP-1) Analogs and Agonists 83
5.1.6.1 Byetta (Exenatide) 84
5.1.6.2 Victoza (Liraglutide) 85
5.1.6.3 Bydureon (Exenatide LAR) 85
5.1.7 Amylin Analog 85
5.1.8 DPP-IV Inhibitors 86
5.1.8.1 Januvia (Sitagliptin) 86
5.1.8.2 Onglyza (Saxagliptin) 86
5.1.8.3 Tradjenta (Linagliptin) 86
5.1.8.4 Galvus (Vildagliptin) 87
5.1.9 Combination Therapy 87
5.1.9.1 Youth with Recent-Onset Type 2 Diabetes should be Started on Combination Therapies 88
5.1.10 Comparisons of the Anti-Diabetes Drugs 88
5.2 Drivers and Trends 89
5.2.1 Market Share of Anti-Diabetic Drugs 89
5.2.2 Forecasts for Anti-Diabetic Drugs 90
5.2.3 Sales Forecast for the Global Diabetes Market 91
5.3 The Future 92
5.3.1 Practice Patterns 92
5.3.2 New Products in Pipeline 92
5.3.2.1 Novel GLP-1 Agonists and Analogs 93
5.3.2.2 Novel DPP-IV Inhibitors 94
5.3.2.3 Sodium Glucose Cotransporter 2 (SGLT-2) 95
5.3.2.4 Emerging Non-Insulin Anti-Diabetes Targets and Drugs in the Pipeline 96
5.3.2.5 Novel Approaches to Finding New Drug Targets 99
5.4 Anti-Diabetic Drug Patent Expiry 100
5.5 Regulatory Issues 100
Request a Sample of this report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=75197
Contact [email protected] for further information.